...
首页> 外文期刊>Pharmacological reports: PR >Structure-cardiovascular activity relationships in a group of new 8-alkylamino-1,3-dimethyl-7-(2-hydroxy-3-aminopropyl)-3,7-dihydro-1H-purine-2,6-diones
【24h】

Structure-cardiovascular activity relationships in a group of new 8-alkylamino-1,3-dimethyl-7-(2-hydroxy-3-aminopropyl)-3,7-dihydro-1H-purine-2,6-diones

机译:一组新的8-烷基氨基-1,3-二甲基-7-(2-羟基-3-氨基丙基)-3,7-二氢-1H-嘌呤-2,6-二酮的结构-心血管活性关系

获取原文
           

摘要

On the basis of our earlier studies in a group of 7,8-disubstituted derivatives of 1,3-dimetyl-3,7-dihydropurine-2,6-dione, a series of new 8-alkylamino-1,3-dimethyl-7-(2-hydroxy-3-aminopropyl)-3,7-dihydropurine-2,6-diones (8-15) were synthesized and tested for their electrocardiographic, antiarrhythmic and hypotensive activity and for ??- and -adrenoreceptor affinities. Among the new derivatives, compounds with the 7-[2-hydroxy-3-(4-phenylpiperazine)-propyl] substituent (9-11) displayed prophylactic antiarrhythmic activity in epinephrine-induced arrhythmia. Analogue 10 with the 8-(2-morpholin-4-yl)-ethylamino group was the most active (ED = 3.9 mg/kg and TI = 59.8), which may indicate that this substituent is preferably important for the antiarrhythmic effect. Only compound 11 with the 8-(2-diethylamino)-ethylamino group significantly decreased the systolic (20.4–28.1%) and diastolic (23.4–33.2%) pressure, but this effect lasted for only 1–5 min. The pharmacologically active compounds 9–11 with the phenylpiperazine moiety showed affinity for ??-receptors (K = 0.143–0.383 μM), but the other compounds were almost (12–15) or completely (8) inactive at this site. Compounds 9–11 and 13–15 displayed moderate to low affinity for -receptors (K = 0.36–2.7 μM).
机译:根据我们较早的研究,在一系列1,3,2-二甲酰基-3,7-二氢嘌呤-2,6-二酮的7,8-二取代衍生物中,一系列新的8-烷基氨基-1,3-二甲基-合成了7-(2-羟基-3-氨基丙基)-3,7-二氢嘌呤-2,6-二酮(8-15),并测试了它们的心电图,抗心律不齐和降压活性以及β-和-肾上腺素受体亲和力。在新的衍生物中,具有7- [2-羟基-3-(4-苯基哌嗪)-丙基]取代基(9-11)的化合物在肾上腺素引起的心律不齐中具有预防性的抗心律不齐活性。具有8-(2-吗啉-4-基)-乙基氨基的类似物10是最具活性的(ED = 3.9mg / kg,TI = 59.8),这表明该取代基优选对于抗心律不齐作用是重要的。只有具有8-(2-二乙氨基)-乙氨基基团的化合物11才能显着降低收缩压(20.4–28.1%)和舒张压(23.4–33.2%),但是这种作用仅持续1-5分钟。具有苯基哌嗪部分的药理活性化合物9-11对γ-受体具有亲和力(K = 0.143-0.383μM),但其他化合物在该位点几乎没有活性(12-15)或完全失活(8)。化合物9-11和13-15显示出对-受体的中等至低亲和力(K = 0.36-2.7μM)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号